id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-314796-bek92zs9	Hartung, Hans-Peter	COVID-19 and management of neuroimmunological disorders	2020-05-22		.txt	text/plain	1313	82	36	The pathogen was identified as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and the diseasecoronavirus disease 2019 (COVID-19) -has caused the first recorded non-influenza pandemic. On the basis of their presumed mode of action and evidence from their use in patients, β-interferons, glatiramer acetate and teriflunomide are safe in COVID-19 because they do not cause relevant immunosuppression or increase the risk of viral infections. Nevertheless, an immediate and ongoing neurological challenge posed by the COVID-19 pandemic is the management of patients who are undergoing immunotherapy for existing neuroimmunological disease. Nevertheless, an immediate and ongoing neurological challenge posed by the COVID-19 pandemic is the management of patients who are undergoing immunotherapy for existing neuroimmunological disease. The complement-blocking mAb eculizumab, which is approved for treatment of NMOSD, has not been associated with an increased risk of viral infections. However, COVID-19 affects the management of patients with neurological diseases in many ways.	./cache/cord-314796-bek92zs9.txt	./txt/cord-314796-bek92zs9.txt